Semaglutide and Heart Health: The SELECT Trial Explained
GLP-1 medication is increasingly seen as cardiometabolic care, not just weight care. SELECT is why. Here is what it found, with honest framing.
What SELECT found
In SELECT (New England Journal of Medicine, 2023; PMID 37952131), Wegovy 2.4 mg, an FDA-approved brand product, reduced major cardiovascular events by about 20% in relative terms. Absolute event rates were 6.5% with the studied product versus 8.0% with placebo in adults with established cardiovascular disease and overweight or obesity, without diabetes. The study did not evaluate compounded preparations.
Why both numbers matter
A "20% reduction" sounds dramatic, and it is meaningful, but honest reporting gives you the absolute numbers too: 6.5% vs 8.0% over the study period. Both are true and both matter. The relative figure shows the size of the effect; the absolute figures show how it plays out across a population.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One-time $199 trial with physician evaluation and, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide; the pharmacy confirms packaging and shipping details before fulfillment. No long-term commitment. Standard care starts with a $119 physician review; medication is separate, and compounded semaglutide programs start at $166/month.
Start the 30-day trialHonest framing. SELECT studied a specific high-risk group (established heart disease plus excess weight) and the brand-name medication. It is not a promise of heart protection for everyone, and compounded semaglutide is not an FDA-approved or brand-identical product. The result is limited to the product, population, and period studied and must not be transferred to a compounded preparation.
The bigger cardiometabolic picture
Blood pressure, triglycerides, and blood sugar may change with weight loss, but the magnitude and direction vary. Clinical follow-up reviews the complete pattern with lab work. Evidence for an approved brand product does not establish a cardiometabolic effect for a compounded preparation.
Put heart evidence in context
Read cardiovascular trial results with both relative and absolute event rates, the enrolled population, the studied product and dose, follow-up length, and the outcome definition. A result for people with established disease does not answer every prevention question. Continue prescribed heart, blood-pressure, cholesterol, or diabetes care unless the responsible clinician changes it.
A compounded semaglutide preparation was not the product tested in SELECT. It is not FDA-approved or brand-identical, and the trial does not establish heart protection for it. Individual monitoring may include symptoms, blood pressure, glucose, lipids, kidney function, and medication tolerance according to clinical need.
Frequently asked questions
Does semaglutide reduce heart attack and stroke risk?
In the SELECT trial (NEJM 2023, PMID 37952131), semaglutide reduced major cardiovascular events by about 20% in relative terms (6.5% vs 8.0% in absolute terms) in adults with established heart disease plus overweight or obesity, without diabetes. It is meaningful evidence for that specific population, not a guarantee for everyone, and it should be discussed with your physician in the context of your own health.
What does the 20% reduction actually mean?
It is a relative reduction: the event rate dropped from 8.0% on placebo to 6.5% on semaglutide over the study period. The 20% describes the size of the effect, and the 6.5% vs 8.0% shows the absolute rates. Honest reporting includes both, because the relative figure alone can overstate the everyday impact.
Do I need heart disease to benefit from a GLP-1?
SELECT does not answer that question outside the studied population and product. Any medication choice depends on indication, risks, alternatives, and the full clinical picture; a compounded preparation does not inherit SELECT's results.
Is compounded semaglutide proven to protect the heart?
SELECT studied Wegovy, an FDA-approved brand product, in a specific population. It did not study a compounded preparation and does not establish heart protection for one. Compounded semaglutide is not FDA-approved or brand-identical, and results vary.
Will my heart medications change on a GLP-1?
Possibly. As weight, blood pressure, and blood sugar improve, your physician may need to adjust blood-pressure, cholesterol, or diabetes medications. That is a physician's decision based on your labs and readings, and it is one reason this kind of care should be supervised rather than managed on your own.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.